Literature DB >> 18949449

BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma.

Gehong Dong1, Cuiling Liu1, Hongtao Ye2,3, Liping Gong4, Jie Zheng1, Min Li1, Xin Huang1, Xuebiao Huang5, Yuanjie Huang1, Yunfei Shi1, Wenjuan Yin1, Zifen Gao6.   

Abstract

The eradication of Helicobacter pylori (H. pylori) with antibiotics induces complete remission in 75% of patients with gastric MALT lymphoma. We investigated the efficacy of H. pylori eradication and assessed the predictive value of BCL10 nuclear expression and t(11;18)(q21;q21) regarding resistance to H. pylori eradication in primary gastric mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) patients from mainland China. Twenty-two gastric MALT cases (Stage I(E)) underwent H. pylori eradication with antibiotics, and sequential endoscopic-bioptic follow-ups were performed and assessed with regular morphologic and immunohistochemical examinations. BCL10 nuclear expression and interphase fluorescence in situ hybridization (FISH) for MALT1 and API2/MALT1 were tested. Thirteen out of the 22 cases (59.1%) achieved complete regression (CR) after the eradication of H. pylori. The longest follow-up period in the 22 patients was 68 months, with 12 patients longer than 24 months. For the 13 CR patients, the longest follow-up period after H. pylori eradication was 53 months, with 6 patients longer than 24 months. BCL10 nuclear expression was detected by immunohistochemical staining in 9 cases, including 7 (77.8%) of 9 cases who showed no response (NR) and 2 (15.4%) of 13 patients who achieved CR following eradication therapy (P < 0.05). t(11;18)(q21;q21) was evaluated by interphase FISH in 18 cases including 11 CR and 7 NR patients after H. pylori eradication. t(11;18)(q21;q21) was found in 4 (57.1%) of 7 patients who showed NR following H. pylori eradication, but one in 11 CR patients (P < 0.05). A total of 59.1% of patients with early gastric MALT lymphoma recruited in this study achieved CR after H. pylori eradication. BCL10 nuclear expression and t(11;18)(q21;q21)-positive gastric MALT lymphomas are likely to be related to a failure to respond to H. pylori eradication in Chinese patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18949449     DOI: 10.1007/s12185-008-0187-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori.

Authors:  Assaad M Soweid; Amer El Sayed
Journal:  Gastrointest Endosc       Date:  2002-03       Impact factor: 9.427

2.  BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma.

Authors:  H Ye; A Dogan; L Karran; T G Willis; L Chen; I Wlodarska; M J Dyer; P G Isaacson; M Q Du
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group.

Authors:  M Sackmann; A Morgner; B Rudolph; A Neubauer; C Thiede; H Schulz; W Kraemer; G Boersch; P Rohde; E Seifert; M Stolte; E Bayerdoerffer
Journal:  Gastroenterology       Date:  1997-10       Impact factor: 22.682

4.  Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication.

Authors:  Thomas Wündisch; Christian Thiede; Andrea Morgner; Astrid Dempfle; Annette Günther; Hongxiang Liu; Hongtao Ye; Ming-Qing Du; Theo D Kim; Ekkehard Bayerdörffer; Manfred Stolte; Andreas Neubauer
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

5.  Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas.

Authors:  M Raderer; B Streubel; S Wöhrer; M Häfner; A Chott
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

6.  Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma.

Authors:  A C Wotherspoon; C Ortiz-Hidalgo; M R Falzon; P G Isaacson
Journal:  Lancet       Date:  1991-11-09       Impact factor: 79.321

7.  T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10.

Authors:  H Liu; H Ye; A Dogan; R Ranaldi; R A Hamoudi; I Bearzi; P G Isaacson; M Q Du
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

8.  MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression.

Authors:  Hongtao Ye; Liping Gong; Hongxiang Liu; Rifat A Hamoudi; Sima Shirali; Liza Ho; Andreas Chott; Berthold Streubel; Reiner Siebert; Stefan Gesk; Jose I Martin-Subero; John A Radford; Sankar Banerjee; Andrew G Nicholson; Renzo Ranaldi; Ellen D Remstein; Zifen Gao; Jie Zheng; Peter G Isaacson; Ahmet Dogan; Ming-Qing Du
Journal:  J Pathol       Date:  2005-02       Impact factor: 7.996

9.  The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.

Authors:  Ellen D Remstein; Ahmet Dogan; Richard R Einerson; Sarah F Paternoster; Stephanie R Fink; Mark Law; Gordon W Dewald; Paul J Kurtin
Journal:  Am J Surg Pathol       Date:  2006-12       Impact factor: 6.394

10.  Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.

Authors:  E Bayerdörffer; A Neubauer; B Rudolph; C Thiede; N Lehn; S Eidt; M Stolte
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321

View more
  8 in total

1.  Sequential H. pylori eradication and radiation therapy with reduced dose compared to standard dose for gastric MALT lymphoma stages IE & II1E: a prospective randomized trial.

Authors:  Renate Schmelz; Stephan Miehlke; Christian Thiede; Stefan Brueckner; Monic Dawel; Matthias Kuhn; Agnes Ruskoné-Formestraux; Manfred Stolte; Christina Jentsch; Jochen Hampe; Andrea Morgner
Journal:  J Gastroenterol       Date:  2018-10-16       Impact factor: 7.527

Review 2.  Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication.

Authors:  Qing Guo; Shanqi Guo; Yizhuo Zhang
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

3.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-03       Impact factor: 0.196

Review 4.  Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas.

Authors:  Marta-Isabel Pereira; José Augusto Medeiros
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

Review 5.  Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis.

Authors:  Angelo Zullo; Cesare Hassan; Alessandro Andriani; Francesca Cristofari; Chiara Bassanelli; Gian Paolo Spinelli; Silverio Tomao; Sergio Morini
Journal:  Med Oncol       Date:  2009-03-24       Impact factor: 3.064

6.  First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Sung-Hsin Kuo; Kun-Huei Yeh; Ming-Shiang Wu; Chung-Wu Lin; Ming-Feng Wei; Jyh-Ming Liou; Hsiu-Po Wang; Li-Tzong Chen; Ann-Lii Cheng
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

Review 7.  Recent Advances in the Genetic of MALT Lymphomas.

Authors:  Juan José Rodríguez-Sevilla; Antonio Salar
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

8.  Association of the virulence factors of Helicobacter pylori and gastric mucosal interleukin-17/23 mRNA expression in dyspeptic patients.

Authors:  Nader Bagheri; Ghorbanali Rahimian; Loghman Salimzadeh; Fatemeh Azadegan; Mahmoud Rafieian-Kopaei; Afshin Taghikhani; Hedayatollah Shirzad
Journal:  EXCLI J       Date:  2013-01-14       Impact factor: 4.068

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.